Is Zydus Lifesciences (ZYDUSLIFE) overvalued or fairly valued?

MarketChacha shows Zydus Lifesciences's valuation in context — a forward P/E of about 24.4, a price-to-book of about 4.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Zydus Lifesciences's revenue?

Zydus Lifesciences reported revenue of ₹11,484 Cr for FY2026, with net profit of ₹3,560 Cr, per official filings.

What is the share price of Zydus Lifesciences (ZYDUSLIFE)?

Zydus Lifesciences last traded at ₹1,141.20 (-0.7% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Zydus Lifesciences

ZYDUSLIFE · NSE · Pharma · India

₹1,141.20-0.7%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:41 AM

Snapshot

TickerZYDUSLIFE

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees29,980

HeadquartersAhmedabad, India

Market cap₹1,14,613 Cr

P/B4.3

Volume1.38L

Websitezyduslife.com

Filings tracked0

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Profile as reported by Yahoo Finance.

Who owns it

Promoters75.2%
Institutions15.1%
Public & other9.7%

171 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend11.4% → 31.0%

Margin has expanded by about 19.6 points — the business is getting more profitable.

Growth qualityrev -13% · PAT 22%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹7,519 Cr

Next fiscal year

Rev ₹33,550 Cr · EPS 47.15

Est. earnings growth +14.5%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹835.5052-wk range₹1,181.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 4

Market cap

₹1,14,613 Cr

Day change

-0.7%

Fwd P/E

24.4

P/B

4.3

Div yield

0.09%

Beta

0.40

Revenue (FY2026)

₹11,484 Cr

Net margin

31.0%

Revenue CAGR (3y)

-12.7%

Profit CAGR (3y)

+22.0%

EPS (FY2026)

35.38

Net profit (FY2026)

₹3,560 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ZYDUSLIFE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹11,484 Cr	₹3,560 Cr	35.38	31.0%
FY2025	₹23,242 Cr	₹4,526 Cr	—	19.5%
FY2024	₹19,547 Cr	₹3,860 Cr	—	19.7%
FY2023	₹17,237 Cr	₹1,960 Cr	—	11.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	₹3,741 Cr	₹1,722 Cr	17.11	46.0%
2025Q4	₹6,865 Cr	₹1,042 Cr	—	15.2%
2025Q3	₹6,123 Cr	₹1,259 Cr	—	20.6%
2025Q2	₹6,574 Cr	₹1,467 Cr	—	22.3%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.